Recent Updates
Recently added Catalysts
SLN Positive Sentiment

Silence Therapeutics to Participate in Three September Investor Conferences

Wednesday, September 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Silence Therapeutics plc announced its participation in three investor conferences in September 2026. The company, known for developing siRNA therapies, will engage with investors through webcasts. This initiative aims to enhance visibility and foster investor relations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple investor conferences highlights company visibility.
  • Engagement with investors through webcasts can enhance investor relations.
  • Focus on novel siRNA therapies positions the company as an innovator.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+199%
120-day peak, hindsight
Typical move
4.5%
average across 4 past catalysts
Lead asset
SLN360
Phase 1 · Hyperlipidemias

Full Press Release Details

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast. Cantor Global Healthcare Conference 2026 Fireside chat on Wednesday, September 9, 2026 at 10:55 a.m. ET H.C. Wainwright 28th Annual Global Investment Conference Fireside chat on Tuesday, September 15, 20

Frequently Asked Questions

What conferences will Silence Therapeutics attend?

Silence Therapeutics will participate in the Cantor Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference.

When is the Cantor Global Healthcare Conference?

The Cantor Global Healthcare Conference is scheduled for September 9, 2026.

How can investors participate in the conferences?

Investors can participate in the conferences via webcast.

What is Silence Therapeutics known for?

Silence Therapeutics is known for developing novel siRNA therapies.

ShareAdd on Google
Tags: SLN Viatris Investor Conferences Healthcare Silence Therapeutics siRNA therapies investor conferences biotechnology
Last updated: Sep 2, 2026

Biotech snapshot

Cash runway
$72M liquidity · $0M/mo burn
Low dilution risk
Lead asset
SLN360Phase 1
Hyperlipidemias →

Catalyst track record

+199%
best trade around SLN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SLN.

See every catalyst's timing & PoA →